Oral Genome is revolutionizing preventive healthcare with its extremely delicate and particular saliva-based, periodontal caries (tooth decay), and diabetes screening check, delivering outcomes that exceed {industry} requirements. With 89.7% sensitivity and 95% specificity, Oral Genome ensures correct illness detection, minimal false positives, and industry-leading reliability.
Not like early Covid-19 exams that confronted scrutiny for inconsistent outcomes, Oral Genome’s rigorous laboratory validation and scientific pilot program affirm its precision. The gadget precisely identifies key biomarkers, together with MMP-8 and P. gingivalis, essential for diagnosing periodontal illness and caries — all in a single, non-invasive check.
Confirmed Accuracy Past Business Requirements
- Sensitivity: 89.7% – Minimizes false negatives for dependable detection.
- Specificity: 95% – Distinguishes disease-free people with confidence.
- Medical Validation – Outperforms commonplace FDA and EU diagnostic accuracy necessities.
“Our objective is to set a brand new benchmark in salivary diagnostics, making certain sufferers and suppliers belief the outcomes,” stated Dr. Tina Noticed, CEO. “Oral Genome eliminates uncertainty, delivering cost-effective level of care salivary testing in preventive healthcare.”
As demand for dependable, non-invasive diagnostics grows, Oral Genome is main the way in which. Its cutting-edge know-how and affordability place it for widespread adoption, reworking oral and systemic well being monitoring.
For extra data, go to www.oralgenome.com or contact [email protected].
Junevity, a biotech that focuses on longevity by growing what they describe as “cell reset therapeutics”, has raised $10 million in seed funding. Goldcrest Capital and Godfrey Capital led the funding spherical. Its know-how depends on licensed analysis by co-founder Dr. Janine Sengstack on the College of California at San Francisco, in line with a press launch.
Junevity makes use of large-scale human knowledge and AI to determine genes or transcription elements that may regulate cell harm and develops siRNA therapeutics in opposition to these targets to return cells to well being. Its preliminary therapeutics beneath improvement will deal with Kind 2 diabetes, weight problems and frailty.
To learn extra, click on right here.
Coral, a Canadian digital care startup supporting ladies getting into perimenopause and menopause, has accomplished a $2.9 million ($4.1 million CAD) seed funding spherical. Brightspark Ventures led the spherical, with participation from Diagram, The51 Ventures, and angel buyers. Coral will use the contemporary capital to help built-in, customized options for care navigation for girls.
To learn extra, click on right here.
Keragon, an AI-powered HIPAA-compliant automation platform for healthcare, has raised $7.5 million in a seed funding spherical. Upfront Ventures led the spherical with buyers Afore Capital, Focal, and 25m Well being including to their preliminary investments. Up to now, Keragon has raised a complete of $10.5 million. The no-code workflow automation platform launched out of stealth in June 2024, in line with a press launch.
To learn extra, click on right here.
The MedCity INVEST Pitch Good contest is at present accepting purposes from startups throughout digital well being, medtech, diagnostics and biopharma. The competition affords the chance for healthcare entrepreneurs to pitch to an viewers of healthcare buyers and stakeholders. The convention will likely be held on the Willis Tower in Chicago on Might 20 and 21. The deadline for purposes is February 21.
To evaluate the factors and submit an software, click on right here.
Credit score: Getty Photos, pixelliebe
It is a paid member characteristic of MedCitizens. Please submit right here and be a part of!
